Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatm...Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatment and detecting relapse.Here,a highly enhanced plasmonic biosensor that can overcome this challenge is developed using atomically thin two-dimensional phase change nanomaterial.By precisely engineering the configuration with atomically thin materials,the phase singularity has been successfully achieved with a significantly enhanced lateral position shift effect.Based on our knowledge,it is the first experimental demonstration of a lateral position signal change>340μm at a sensing interface from all optical techniques.With this enhanced plasmonic effect,the detection limit has been experimentally demonstrated to be 10^(-15) mol L^(−1) for TNF-α cancer marker,which has been found in various human diseases including inflammatory diseases and different kinds of cancer.The as-reported novel integration of atomically thin Ge_(2)Sb_(2)Te_(5) with plasmonic substrate, which results in a phase singularity and thus a giant lateral position shift, enables the detection of cancer markers with low molecular weight at femtomolar level. These results will definitely hold promising potential in biomedical application and clinical diagnostics.展开更多
基金We thank Shiyue Liu from School of Life Sciences in The Chinese University of Hong Kong for helpful discussions.This work is supported under the PROCORE-France/Hong Kong Joint Research Scheme(F-CUHK402/19)the Research Grants Council,Hong Kong Special Administration Region(AoE/P-02/12,14210517,14207419,N_CUHK407/16)the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie Grant Agreement No.798916.Y.Wang is supported under the Hong Kong PhD Fellowship Scheme.
文摘Detection of small cancer biomarkers with low molecular weight and a low concentration range has always been challenging yet urgent in many clinical applications such as diagnosing early-stage cancer,monitoring treatment and detecting relapse.Here,a highly enhanced plasmonic biosensor that can overcome this challenge is developed using atomically thin two-dimensional phase change nanomaterial.By precisely engineering the configuration with atomically thin materials,the phase singularity has been successfully achieved with a significantly enhanced lateral position shift effect.Based on our knowledge,it is the first experimental demonstration of a lateral position signal change>340μm at a sensing interface from all optical techniques.With this enhanced plasmonic effect,the detection limit has been experimentally demonstrated to be 10^(-15) mol L^(−1) for TNF-α cancer marker,which has been found in various human diseases including inflammatory diseases and different kinds of cancer.The as-reported novel integration of atomically thin Ge_(2)Sb_(2)Te_(5) with plasmonic substrate, which results in a phase singularity and thus a giant lateral position shift, enables the detection of cancer markers with low molecular weight at femtomolar level. These results will definitely hold promising potential in biomedical application and clinical diagnostics.
